Cargando…

Preclinical modeling of myelodysplastic syndromes

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rouault-Pierre, K, Mian, S A, Goulard, M, Abarrategi, A, Di Tulio, A, Smith, A E, Mohamedali, A, Best, S, Nloga, A-M, Kulasekararaj, A G, Ades, L, Chomienne, C, Fenaux, P, Dosquet, C, Mufti, G J, Bonnet, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729336/ https://www.ncbi.nlm.nih.gov/pubmed/28663577 http://dx.doi.org/10.1038/leu.2017.172

Ejemplares similares

Role of the microenvironment in myeloid malignancies
por: Goulard, Marie, et al.
Publicado: (2017)

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment
por: Mian, Syed A., et al.
Publicado: (2015)

Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches
por: Abarrategi, Ander, et al.
Publicado: (2018)

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
por: Vidal, Valérie, et al.
Publicado: (2017)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
por: Platzbecker, U, et al.
Publicado: (2014)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?
por: Kouroupi, E, et al.
Publicado: (2012)

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
por: Mian, Syed A., et al.
Publicado: (2021)

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis
por: Alkhatabi, Heba A., et al.
Publicado: (2016)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
por: Di Tullio, Alessandro, et al.
Publicado: (2017)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
por: Cluzeau, Thomas, et al.
Publicado: (2017)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice
por: Patel, S, et al.
Publicado: (2015)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

Treatment of Acute Promyelocytic Leukemia with High White Cell Blood Counts.
por: Kelaidi, C., et al.
Publicado: (2011)

A functional assay for microRNA target identification and validation
por: Gäken, Joop, et al.
Publicado: (2012)

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
por: Kittang, Astrid Olsnes, et al.
Publicado: (2015)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
por: Kubasch, A. S., et al.
Publicado: (2023)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome
por: Garelius, H. K. G., et al.
Publicado: (2016)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment
por: Caye, Aurélie, et al.
Publicado: (2020)

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment
por: Caye, Aurélie, et al.
Publicado: (2019)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
por: Schmitt, Nanni, et al.
Publicado: (2021)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Managing myelodysplastic symptoms in elderly patients
por: Ria, R, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_btfqdlf4fbch2d26ufgs9sm06a